Pharmaceutical compositions are proposed of optimal dosage amounts that can provide maximum therapeutic effects, namely fat content reducing, in patients, including a first version of composition for fat content reducing, suitable for subcutaneous injection and comprising (a) 5 ng to 20 μg of a fat tissue reducing, long-acting, lipophilic selective beta-2 adrenergic receptor agonist, chosen from salmeterol, formoterol, or salts thereof； and (b) a glucocorticosteroid, chosen from dexamethasone, prednisolone, fluticasone, budesonide, or salts thereof, or combination thereof； (c) at least one non-active, suitable for subcutaneous injection ingredient, wherein the said non-active, suitable for subcutaneous injection ingredient is chosen from polysorbate-80 in an amount of 0.01 to 10%, or co-solvent such as polyethylene glycol in an amount of 0.25 to 40%, and also proposed is a second version of composition differing from the first version in that it can provide an average concentration Cmax of long-acting, lipophilic selective beta-2 adrenergic receptor agonist in plasma equal or below 300 pg/ml in subcutaneous injection, additionally, a third version of composition differs in that proportion of the long-acting selective beta-2 adrenergic receptor agonist to the glucocorticosteroid is 400:1 to 1:400, a fourth version of composition differs in that proportion of the long-acting selective beta-2 adrenergic receptor agonist to the glucocorticosteroid is 200:1 to 1:200, and a fifth version of composition includes a composition according to the first version, wherein long-acting, lipophilic selective beta-2 adrenergic receptor agonist is salmeterol xinafoate, a sixth version of composition includes a composition according to any of first five versions, wherein a glucocorticosteroid is fluticasone propionate, and a seventh version of composition includes a composition according to any of first six versions, wherein a glucocorticosteroid is comprised in an amount of less than
